EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Risk factors for liver enzyme elevation with remdesivir use in the treatment of paediatric COVID‐19

Tsuyoshi Jinda, Shinsuke Mizuno iD, Shunsuke Tatami, Masashi Kasai, Tatsuhiko Ishida

Journal of Paediatrics and Child Health · 2024

DOI: 10.1111/jpc.16569 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Paediatrics and Child Health, 2024. Verfasst von Tsuyoshi Jinda und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Pediatrics, Hyogo Prefectural Kobe Children's Hospital, Kobe, Hyogo, Japan. Hauptthemen laut MEDLINE: Adenosine Monophosphate, Antiviral Agents, COVID-19 Drug Treatment. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Remdesivir (RDV) causes liver enzyme elevation in adults; however, the frequency of this elevation in children and the associated risk factors are largely unknown. Therefore, we aimed to examine risk factors for liver enzyme elevation in hospitalised paediatric patients who received RDV.

Methods

This was a retrospective case–control study of all patients aged

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenosine MonophosphateAntiviral AgentsCOVID-19 Drug TreatmentHumansRetrospective StudiesMaleFemaleChildRisk FactorsCase-Control StudiesChild, PreschoolAdolescentInfantAlanine TransaminaseAlanineCOVID-19SARS-CoV-2LiverAspartate Aminotransferases

Stichwörter der Autor:innen

liver enzyme elevationpaediatric COVID‐19remdesivir

Substanzen

remdesivirAdenosine MonophosphateAntiviral AgentsAlanine TransaminaseAlanineAspartate Aminotransferases

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Pediatrics, Hyogo Prefectural Kobe Children's Hospital, Kobe, Hyogo, Japan.
  • Department of Pharmacy, Hyogo Prefectural Kobe Children's Hospital, Kobe, Hyogo, Japan.

ORCID-Profile: Shinsuke Mizuno

Zitieren

APA

Jinda, T., Mizuno, S., Tatami, S., Kasai, M., & Ishida, T. (2024). Risk factors for liver enzyme elevation with remdesivir use in the treatment of paediatric COVID‐19. Journal of Paediatrics and Child Health. https://doi.org/10.1111/jpc.16569

Vancouver

Jinda T, Mizuno S, Tatami S, Kasai M, Ishida T. Risk factors for liver enzyme elevation with remdesivir use in the treatment of paediatric COVID‐19. Journal of Paediatrics and Child Health. 2024. doi:10.1111/jpc.16569

BibTeX
@article{Jinda2024,
  author = {Jinda, Tsuyoshi and Mizuno, Shinsuke and Tatami, Shunsuke and Kasai, Masashi and Ishida, Tatsuhiko},
  title = {Risk factors for liver enzyme elevation with remdesivir use in the treatment of paediatric COVID‐19},
  journal = {Journal of Paediatrics and Child Health},
  year = {2024},
  doi = {10.1111/jpc.16569}
}
Kostenlos starten →